In summary, hepatic CD8+PD1+ T cells did not cause tumour regression during NASH, but rather were linked to HCC development, which was enhanced by anti-PD1 immunotherapy. This evidence concerns the gene CD8A and metabolic dysfunction-associated steatohepatitis.